Peter Houghton

Summary

Affiliation: Nationwide Children's Hospital
Country: USA

Publications

  1. pmc Anti-angiogenic activity of a small molecule STAT3 inhibitor LLL12
    Hemant K Bid
    Center for Childhood Cancer, Nationwide Children s Hospital, Columbus, Ohio, United States of America
    PLoS ONE 7:e35513. 2012
  2. pmc Targeting angiogenesis in childhood sarcomas
    Hemant K Bid
    Center for Childhood Cancer, Nationwide Children s Hospital, 700 Children s Drive, Columbus, OH 43205, USA
    Sarcoma 2011:601514. 2011
  3. pmc RAC1: an emerging therapeutic option for targeting cancer angiogenesis and metastasis
    Hemant K Bid
    Corresponding Author Peter J Houghton, Center for Childhood Cancer, The Research Institute, Nationwide Children s Hospital, 700 Children s Drive, Columbus, OH 43205
    Mol Cancer Ther 12:1925-34. 2013
  4. pmc Potent inhibition of angiogenesis by the IGF-1 receptor-targeting antibody SCH717454 is reversed by IGF-2
    Hemant K Bid
    Center for Childhood Cancer, The Research Institute, Nationwide Children s Hospital, 700 Children s Drive, Columbus, OH 43205, USA
    Mol Cancer Ther 11:649-59. 2012
  5. pmc Initial testing (stage 1) of LCL161, a SMAC mimetic, by the Pediatric Preclinical Testing Program
    Peter J Houghton
    Nationwide Children s Hospital, Columbus, Ohio 43205, USA
    Pediatr Blood Cancer 58:636-9. 2012
  6. pmc Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing Program
    Peter J Houghton
    Center for Children s Cancer, Nationwide Children s Hospital, Columbus, Ohio 43205, USA
    Mol Cancer Ther 9:101-12. 2010
  7. doi request reprint Initial testing of the hypoxia-activated prodrug PR-104 by the pediatric preclinical testing program
    Peter J Houghton
    Nationwide Children s Hospital, Columbus, OH, USA
    Pediatr Blood Cancer 57:443-53. 2011
  8. pmc Testing of the topoisomerase 1 inhibitor Genz-644282 by the pediatric preclinical testing program
    Peter J Houghton
    Nationwide Children s Hospital, Columbus, OH, USA
    Pediatr Blood Cancer 58:200-9. 2012
  9. doi request reprint Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program
    Peter J Houghton
    Nationwide Children s Hospital, Columbus, OH, USA
    Pediatr Blood Cancer 58:191-9. 2012
  10. pmc Everolimus
    Peter J Houghton
    Center for Childhood Cancer, The Research Institute, Nationwide Children s Hospital, Columbus, Ohio 43205, USA
    Clin Cancer Res 16:1368-72. 2010

Collaborators

Detail Information

Publications13

  1. pmc Anti-angiogenic activity of a small molecule STAT3 inhibitor LLL12
    Hemant K Bid
    Center for Childhood Cancer, Nationwide Children s Hospital, Columbus, Ohio, United States of America
    PLoS ONE 7:e35513. 2012
    ..STAT3 inhibitors have been shown to reduce tumor microvessel density in tumors but a direct anti-angiogenic activity has not been described...
  2. pmc Targeting angiogenesis in childhood sarcomas
    Hemant K Bid
    Center for Childhood Cancer, Nationwide Children s Hospital, 700 Children s Drive, Columbus, OH 43205, USA
    Sarcoma 2011:601514. 2011
    ..Here we review the literature on blood vessel formation in sarcomas with a focus on pediatric sarcomas and developments in targeting angiogenesis for treatment of these rare cancers...
  3. pmc RAC1: an emerging therapeutic option for targeting cancer angiogenesis and metastasis
    Hemant K Bid
    Corresponding Author Peter J Houghton, Center for Childhood Cancer, The Research Institute, Nationwide Children s Hospital, 700 Children s Drive, Columbus, OH 43205
    Mol Cancer Ther 12:1925-34. 2013
    ..Understanding these mechanisms may provide insight into RAC1 signaling components as alternative therapeutic targets for tumor angiogenesis and metastasis...
  4. pmc Potent inhibition of angiogenesis by the IGF-1 receptor-targeting antibody SCH717454 is reversed by IGF-2
    Hemant K Bid
    Center for Childhood Cancer, The Research Institute, Nationwide Children s Hospital, 700 Children s Drive, Columbus, OH 43205, USA
    Mol Cancer Ther 11:649-59. 2012
    ..Many childhood cancers secrete IGF-2, suggesting that tumor-derived IGF-2 in the microenvironment maintains angiogenesis in the presence of IGF-1R-targeted antibodies allowing tumor progression...
  5. pmc Initial testing (stage 1) of LCL161, a SMAC mimetic, by the Pediatric Preclinical Testing Program
    Peter J Houghton
    Nationwide Children s Hospital, Columbus, Ohio 43205, USA
    Pediatr Blood Cancer 58:636-9. 2012
    ..No objective tumor responses were observed. In vivo LCL161 demonstrated limited single agent activity against the pediatric preclinical models studied...
  6. pmc Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing Program
    Peter J Houghton
    Center for Children s Cancer, Nationwide Children s Hospital, Columbus, Ohio 43205, USA
    Mol Cancer Ther 9:101-12. 2010
    ....
  7. doi request reprint Initial testing of the hypoxia-activated prodrug PR-104 by the pediatric preclinical testing program
    Peter J Houghton
    Nationwide Children s Hospital, Columbus, OH, USA
    Pediatr Blood Cancer 57:443-53. 2011
    ..PR-104 activation can occur via hypoxia-dependent reductases and also independently of hypoxia by aldo-keto reductase (AKR) 1C3...
  8. pmc Testing of the topoisomerase 1 inhibitor Genz-644282 by the pediatric preclinical testing program
    Peter J Houghton
    Nationwide Children s Hospital, Columbus, OH, USA
    Pediatr Blood Cancer 58:200-9. 2012
    ..Genz-644282 is a novel non-camptothecin topoisomerase I poison that is in clinical development...
  9. doi request reprint Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program
    Peter J Houghton
    Nationwide Children s Hospital, Columbus, OH, USA
    Pediatr Blood Cancer 58:191-9. 2012
    ..Procedures AZD8055 was tested against the PPTP in vitro panel at concentrations ranging from 1.0 nM to 10 µM and against the PPTP in vivo panels at a dose of 20 mg/kg administered orally daily x 7 for 4 weeks...
  10. pmc Everolimus
    Peter J Houghton
    Center for Childhood Cancer, The Research Institute, Nationwide Children s Hospital, Columbus, Ohio 43205, USA
    Clin Cancer Res 16:1368-72. 2010
    ..Further, biomarkers that predict tumor sensitivity are still elusive. The mechanism of action, preclinical antitumor activity, and clinical activity of everolimus against RCC are reviewed...
  11. doi request reprint Small molecules, LLL12 and FLLL32, inhibit STAT3 and exhibit potent growth suppressive activity in osteosarcoma cells and tumor growth in mice
    Grace Ifeyinwa Onimoe
    Center for Childhood Cancer, The Research Institute at Nationwide Children s Hospital, Columbus, OH, USA
    Invest New Drugs 30:916-26. 2012
    ..Blocking persistent STAT3 signaling by LLL12 and FLLL32 may be a novel therapeutic approach for osteosarcoma...
  12. pmc Hepatic loss of miR-122 predisposes mice to hepatobiliary cyst and hepatocellular carcinoma upon diethylnitrosamine exposure
    Shu Hao Hsu
    Department of Molecular and Cellular Biochemistry, The Ohio State University, Columbus, Ohio Department of Molecular, Cellular and Developmental Biology Program, The Ohio State University, Columbus, Ohio
    Am J Pathol 183:1719-30. 2013
    ..Collectively, miR-122 depletion facilitates cystogenesis and hepatocarcinogenesis in mice on DEN challenge by up-regulating several genes involved in proliferation, growth factor signaling, neovascularization, and metastasis...
  13. doi request reprint mTORC1 signaling under hypoxic conditions is controlled by ATM-dependent phosphorylation of HIF-1α
    Hakan Cam
    Center for Childhood Cancer, Nationwide Children s Hospital, Columbus, OH 43205, USA
    Mol Cell 40:509-20. 2010
    ..Deregulation of these pathways in pediatric solid tumor xenografts suggests a link between mTORC1 dysregulation and solid tumor development and points to an important role for hypoxic regulation of mTORC1 activity in tumor development...

Research Grants16

  1. Rapamycin-induced Selective Apoptosis in Malignant Cells
    Peter J Houghton; Fiscal Year: 2010
    ..The studies have the potential to radically alter outcome for these children, and reduce the debilitating sequellae of high dose radiation and chemotherapy. ..
  2. RAPAMYCIN INDUCED SELECTIVE APOPTOSIS IN MALIGNANT CELLS
    Peter Houghton; Fiscal Year: 1999
    ..The long-term goal of these studies is to develop alternative curative therapy for children with cancer that will avoid the often devastating events, associated with contemporary intensive chemo-radiotherapy regimens. ..
  3. Rapamycin-induced Selective Apoptosis in Malignant Cells
    Peter Houghton; Fiscal Year: 2006
    ..e. p53 or p21Cip1. Our studies will develop the biochemical framework to underpin a novel approach by which rapamycins can induce tumor-selective cytotoxicity based on the loss of the tumor suppressor p53. ..
  4. Rapamycin-induced Selective Apoptosis in Malignant Cells
    Peter Houghton; Fiscal Year: 2005
    ..e. p53 or p21Cip1. Our studies will develop the biochemical framework to underpin a novel approach by which rapamycins can induce tumor-selective cytotoxicity based on the loss of the tumor suppressor p53. ..
  5. Rapamycin-induced Selective Apoptosis in Malignant Cells
    Peter Houghton; Fiscal Year: 2004
    ..e. p53 or p21Cip1. Our studies will develop the biochemical framework to underpin a novel approach by which rapamycins can induce tumor-selective cytotoxicity based on the loss of the tumor suppressor p53. ..
  6. Rapamycin-induced Selective Apoptosis in Malignant Cells
    Peter Houghton; Fiscal Year: 2003
    ..e. p53 or p21Cip1. Our studies will develop the biochemical framework to underpin a novel approach by which rapamycins can induce tumor-selective cytotoxicity based on the loss of the tumor suppressor p53. ..
  7. RAPAMYCIN INDUCED SELECTIVE APOPTOSIS IN MALIGNANT CELLS
    Peter Houghton; Fiscal Year: 2002
    ..The long-term goal of these studies is to develop alternative curative therapy for children with cancer that will avoid the often devastating events, associated with contemporary intensive chemo-radiotherapy regimens. ..
  8. MTOR as a Therapeutic Target in Childhood Cancer
    Peter Houghton; Fiscal Year: 2003
    ..abstract_text> ..
  9. MTOR as a Therapeutic Target in Childhood Cancer
    Peter Houghton; Fiscal Year: 2002
    ..abstract_text> ..
  10. MTOR as a Therapeutic Target in Childhood Cancer
    Peter Houghton; Fiscal Year: 2005
    ..abstract_text> ..
  11. RAPAMYCIN INDUCED SELECTIVE APOPTOSIS IN MALIGNANT CELLS
    Peter Houghton; Fiscal Year: 2001
    ..The long-term goal of these studies is to develop alternative curative therapy for children with cancer that will avoid the often devastating events, associated with contemporary intensive chemo-radiotherapy regimens. ..
  12. Rapamycin-induced Selective Apoptosis in Malignant Cells
    Peter Houghton; Fiscal Year: 2007
    ..e. p53 or p21Cip1. Our studies will develop the biochemical framework to underpin a novel approach by which rapamycins can induce tumor-selective cytotoxicity based on the loss of the tumor suppressor p53. ..
  13. RAPAMYCIN INDUCED SELECTIVE APOPTOSIS IN MALIGNANT CELLS
    Peter Houghton; Fiscal Year: 2000
    ..The long-term goal of these studies is to develop alternative curative therapy for children with cancer that will avoid the often devastating events, associated with contemporary intensive chemo-radiotherapy regimens. ..
  14. Rapamycin-induced Selective Apoptosis in Malignant Cells
    Peter Houghton; Fiscal Year: 2009
    ..The studies have the potential to radically alter outcome for these children, and reduce the debilitating sequellae of high dose radiation and chemotherapy. ..
  15. MTOR as a Therapeutic Target in Childhood Cancer
    Peter Houghton; Fiscal Year: 2004
    ..abstract_text> ..